Core 2: Neuro-Imaging Core

核心2：神经成像核心(NIC) 摘要/摘要 胶质母细胞瘤(GBM)预后极差，缺乏有效的治疗方法。 公共卫生问题。虽然传统的MRI技术在确定GBM对常见疾病的反应方面很有价值 抗肿瘤疗法、包括免疫疗法、抗血管生成剂或疗法在内的新疗法 改变肿瘤新陈代谢可能导致放射学改变，很难与非 有反应性的或正在生长的肿瘤。因此，神经成像核心(NIC)的主要目标将是提供 先进的MRI和PET成像支持，建立了与孢子项目的可靠性和一致性 为他们各自的项目进行调查。具体地说，NIC将使用定量核磁共振和正电子发射计算机断层扫描 临床成像(目标1)和最先进的MR和PET成像采集、高级后处理和 在新的临床试验中用于患者临床成像的新分析工具(目标2)。因此，此核心将添加 通过帮助研究人员更好地了解原位代谢、生理和 脑和肿瘤内的传统放射学改变，以解决每一个特定的目标 加州大学洛杉矶分校的脑癌孢子项目。NIC的另一个主要目标是了解 代谢和/或生理成像和肿瘤生物学，以便可靠地描绘治疗反应 相对于复发肿瘤(目标3)，这反过来将促进新的MR-PET伴侣的直接翻译 生物标志物/技术用于临床评估正在进行的和新的治疗方法的疗效 由孢子项目和核心产生的临床试验。

Core 2: Neuro-Imaging Core (NIC) SUMMARY/ABSTRACT The extremely poor prognosis and lack of effective treatments for glioblastoma (GBM) remains a significant public health issue. While traditional MRI techniques are valuable in determining GBM response to common anti-neoplastic therapies, novel treatments including immunotherapies, anti-angiogenic agents, or therapies that alter tumor metabolism may result in radiographic changes that are challenging to differentiate from non- responsive or growing tumor. Therefore, the primary goal of the Neuro-Imaging Core (NIC) will be to provide advanced MRI and PET imaging support with established reliability and consistency to SPORE project investigators for their respective projects. Specifically, the NIC will use quantitative MRI and PET for pre- clinical imaging (Aim 1) and state-of-the-art MR and PET imaging acquisition, advanced post-processing, and novel analysis tools for clinical imaging of patients in novel clinical trials (Aim 2). Hence, this Core will add value to the overall SPORE by helping investigators to better understand the in situ metabolic, physiologic, and traditional radiographic changes within the brain and tumor in order to address specific objectives of each of the UCLA Brain Cancer SPORE projects. Another main goal of the NIC is to understand the link between metabolic and/or physiologic imaging and tumor biology in order to reliably delineate treatment response versus recurrent tumor (Aim 3), which in turn will facilitate the direct translation of new MR-PET companion biomarkers/techniques to the clinic for the evaluation of treatment response in ongoing and new therapeutic clinical trials resulting from the SPORE projects and cores.